Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

How to Audit Biologic Tissue Suppliers for FDA Registration

Published November 20, 2026

Primary Regulatory Framework
21 CFR Part 1271

The federal regulation governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), covering establishment registration, donor eligibility, and Current Good Tissue Practice (CGTP).

Registration Renewal Cadence
Annual (December)

Registered tissue establishments are mandated by the FDA to submit annual registration updates every December via the electronic eHCTERS portal.

Statutory Pathways
PHS Act 361 vs. 351

Section 361 covers minimally manipulated tissues for homologous use without pre-market approval; Section 351 covers more-than-minimally manipulated biologics requiring an IND or BLA.

To audit biologic tissue suppliers for FDA registration, practices must cross-reference the supplier's registered establishment name and Form 3356 filings directly against federal records rather than relying on distributor compliance letters. Because an active registration verifies administrative reporting rather than product clearance, clinical directors evaluating biologics must also inspect lot-specific donor screening panels, continuous cold-chain monitoring logs, and state wholesale distribution licensing. This systematic audit process eliminates regulatory exposure and protects clinical service lines from unannounced allograft recalls.

Understanding the Regulatory Landscape for Biologics

For medical practice managers overseeing procurement in orthopedics, pain management, or aesthetics, onboarding a new vendor for regenerative biologics—such as Wharton's Jelly, amniotic allografts, cord blood, or MSC exosomes—carries significant operational responsibility. A common misconception in clinic procurement is that an "FDA-registered" certificate presented by a sales representative serves as an FDA endorsement or product approval.

In reality, establishment registration under 21 CFR Part 1271 simply means the facility has notified the FDA that it manufactures, processes, stores, or distributes human cells, tissues, and cellular and tissue-based products (HCT/Ps). Registration is mandatory, automatic upon filing, and does not constitute a pre-market approval of the products themselves. Therefore, learning how to audit biologic tissue suppliers for FDA registration requires looking past marketing materials and evaluating the primary regulatory documentation.

Section 361 vs. Section 351 Products

Before querying the FDA database, administrators must understand the two primary regulatory tiers under the Public Health Service (PHS) Act:

  • Section 361 HCT/Ps: These products are regulated solely under 21 CFR Part 1271 and do not require pre-market FDA approval (an IND or BLA). To qualify as a 361 product, the tissue must meet strict criteria: it must be minimally manipulated, intended for homologous use only, not combined with another article (with limited exceptions), and have no systemic effect or dependence on the metabolic activity of living cells for its primary function (unless for autologous use or specific reproductive/first-degree relative scenarios).
  • Section 351 HCT/Ps: Any biologic product that fails to meet all criteria of Section 361—for instance, a product that is more than minimally manipulated via enzymatic digestion or expansion in culture—is regulated as a drug, device, or biological product under Section 351. These require an active Investigational New Drug (IND) application or an approved Biologics License Application (BLA) to be lawfully marketed and distributed.

When auditing a vendor, misalignment between how a product is processed (e.g., heavily processed cellular products) and how it is marketed (e.g., claiming 361 status while making systemic or non-homologous promotional claims) is a primary compliance red flag.

Step-by-Step Checklist: Auditing a Biologic Supplier

Practice managers should standardize their vendor qualification process by requiring prospective suppliers to pass a formal document audit before any products enter the clinic's inventory. Use the following checklist to verify compliance.

  • Obtain the Manufacturer’s Legal Name and FEI Number: Distributors often private-label products or operate under a DBA. Request the exact legal entity name and FDA Establishment Identifier (FEI) of the processing laboratory where the tissue is actually recovered, processed, and packaged.
  • Query the FDA eHCTERS Public Database: Navigate directly to the FDA's public Human Cell and Tissue Establishment Registration database. Do not rely solely on a PDF certificate provided by the vendor, as registrations must be renewed annually every December. Search by the FEI number or legal name.
  • Verify Registration Status and Functions: Confirm that the establishment’s status is listed as "Active" or "Registered." Review the specific HCT/P types listed (e.g., amniotic membrane, umbilical cord, Wharton's jelly) and the functions performed (recover, screen, test, package, process, store, label, distribute) to ensure they match the products being pitched to your practice.
  • Screen for FDA Enforcement Actions: Search the FDA’s Warning Letters database and Inspection Classification Database using the manufacturer's legal name. Determine if the facility has received an Untitled Letter, a Warning Letter regarding unapproved 351 products, or a Form FDA 483 with an "Official Action Indicated" (OAI) status following an inspection.
  • Audit Donor Eligibility and Infectious Disease Testing: Under 21 CFR Part 1271 Subpart C, manufacturers must screen and test donors for relevant communicable disease agents (including HIV, Hepatitis B and C, Treponema pallidum, and where applicable, HTLV, CMV, and Zika). Request a sample Certificate of Analysis (CoA) and package insert to verify that donor testing is performed by an FDA-registered, CLIA-certified laboratory using FDA-licensed, approved, or cleared screening tests.
  • Verify Voluntary Industry Accreditations: While not a substitute for FDA registration, accreditation by the American Association of Tissue Banks (AATB) or the Association for the Advancement of Blood & Biotherapies (AABB) indicates that the facility submits to rigorous, recurring third-party inspections of its Standard Operating Procedures (SOPs) and quality management systems.
  • Confirm Distributor State Licensing and Cold-Chain SOPs: If you are purchasing through a third-party distributor rather than directly from the processing lab, verify the distributor's credentials. Ensure they hold appropriate state-level medical device or wholesale distributor licenses (for example, Dallas Regenerative Solutions operates under Texas medical device distributor license #1002308) and have validated cold-chain shipping protocols to prevent product degradation during transit.

Clinical Perspective: Why Compliance Audits Protect Patient Outcomes

While the practice manager focuses on supply chain risk, vendor contracts, and regulatory liability, the treating physicians—whether they are orthopedic doctors or pain management doctors—have a different primary concern: clinical predictability, tissue integrity, and patient safety.

For the clinician, a rigorous supplier audit is directly tied to biological consistency at the point of care. When a tissue bank shortcuts Current Good Tissue Practice (CGTP) regulations under 21 CFR Part 1271 Subpart D, the clinical consequences fall into two categories: contamination risk and loss of structural or biochemical integrity.

First, inadequate donor screening or poor aseptic processing techniques introduce the risk of transmitting communicable diseases or bacterial endotoxins to the patient. An articular injection or dermal application of a compromised allograft can result in severe acute inflammatory reactions or localized infections, immediately jeopardizing patient health and the physician's medical license.

Second, improper processing, lyophilization, or cryopreservation—or a break in the distributor's cold-chain logistics—can denature the extracellular matrix proteins, cytokines, and structural components that the clinician relies upon. If a cryogenically preserved product thaws and refreezes during unvalidated transit, ice crystal formation can shear structural matrices, rendering the treatment inconsistent. By enforcing strict vendor audits at the administrative level, the practice manager ensures that the clinician receives a standardized, reproducible biologic product that performs as expected in the treatment room.

Evaluating the Distributor’s Role in Your Supply Chain

Many medical practices prefer working with an established regenerative medicine distributor rather than managing separate accounts with multiple individual tissue banks, compounding pharmacies, and equipment manufacturers. A qualified distributor acts as an initial filter, vetting manufacturing labs for CGTP compliance before adding products to their catalog.

When evaluating a distribution partner, ask how they qualify their upstream laboratories, how they handle adverse event reporting and tissue tracking (which requires maintaining records that allow tracking of an HCT/P from the donor to the consignee and vice versa), and whether they provide clear documentation for every lot number shipped to your clinic. You can learn more about our history, licensing, and vendor standards on our about page.

What This Means for Your Practice

To insulate your clinic from regulatory disruption and ensure consistent inventory quality, implement the following operational steps immediately:

  1. Build a Compliance Binder for Current Inventory: Pull the package inserts and Certificates of Analysis for all allografts, exosomes, or tissue products currently stored in your clinic's refrigerators or cryogenic freezers. Run every manufacturing lab through the FDA eHCTERS database and the FDA Warning Letters database today.
  2. Standardize Your Vendor Onboarding SOP: Do not allow clinical staff or providers to trial or purchase new biologic products without first submitting the vendor's FEI number and sample documentation to the practice administrator for a formal 7-step audit.
  3. Audit Your Marketing Alignment: Review your practice’s internal patient education brochures, consent forms, and website copy. Ensure that your clinic is not inadvertently making drug claims or non-homologous use claims about 361 tissue products, as enforcement bodies review both supplier and clinical marketing materials.
  4. Consolidate with Vetted Partners: Streamline procurement and compliance tracking by working with licensed distributors who maintain transparent relationships with compliant, AATB-accredited and FDA-registered tissue establishments.

If your practice is currently reviewing its regenerative medicine supply chain, adding new service lines, or looking to consolidate procurement of vetted biologics and clinical devices, our team can help you navigate vendor selection and workflow integration. Reach out through our contact page to schedule an operational consultation with Dallas Regenerative Solutions.

Frequently asked questions

Does FDA registration mean a biologic product is FDA approved?
No. Registration under 21 CFR Part 1271 means the establishment has notified the FDA that it processes or distributes human cells or tissues (HCT/Ps) and is subject to FDA inspection. Products regulated solely under Section 361 do not undergo pre-market FDA approval, whereas Section 351 products require an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application.
How often must a tissue bank renew its FDA establishment registration?
Under 21 CFR 1271.21, establishments that manufacture HCT/Ps must update their registration with the FDA annually every December, even if no changes have occurred to their product listings. Practice managers should re-verify their suppliers in the eHCTERS database during the first quarter of each year.
What is the difference between CGTP and cGMP in biologic manufacturing?
Current Good Tissue Practice (CGTP) under 21 CFR Part 1271 governs the methods, facilities, and controls used to prevent the introduction, transmission, or spread of communicable diseases in HCT/Ps. Current Good Manufacturing Practice (cGMP) under 21 CFR Parts 210 and 211 is a broader drug manufacturing standard that also applies to Section 351 biological products, focusing heavily on identity, strength, quality, and purity.
Do medical distributors need to be registered in the FDA tissue database?
If an entity takes physical possession of HCT/Ps to store or distribute them, they are generally required to register as an establishment under 21 CFR Part 1271. However, if a company acts solely as a broker or sales agent and the product is drop-shipped directly from the registered processing laboratory to the clinic, the lab's registration covers the physical distribution, while the distributor must comply with applicable state-level medical distribution licensing.
What records must a medical practice keep after receiving biologic tissues?
While the primary burden of donor-to-consignee tracking falls on the manufacturing establishment, medical practices should maintain strict internal logs recording the product name, manufacturer, unique lot or serial number, expiration date, storage temperature logs, and the specific patient chart to which the tissue was applied. This ensures rapid compliance in the event of a manufacturer recall or adverse event investigation.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →